Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease.

Samantha Gunning, Rita L McGill, Arlene B Chapman, Pranav S Garimella
{"title":"Peritoneal Dialysis Outcomes in Autosomal Dominant Polycystic Kidney Disease.","authors":"Samantha Gunning, Rita L McGill, Arlene B Chapman, Pranav S Garimella","doi":"10.2215/CJN.0000001134","DOIUrl":null,"url":null,"abstract":"<p><strong>Key points: </strong>Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time.</p><p><strong>Background: </strong>Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States.</p><p><strong>Methods: </strong>A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion.</p><p><strong>Results: </strong>Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year.</p><p><strong>Conclusions: </strong>These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":"1762-1771"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668241/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of the American Society of Nephrology : CJASN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2215/CJN.0000001134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Key points: Peritoneal dialysis can be used successfully in patients with autosomal dominant polycystic kidney disease. Compared with days receiving hemodialysis, peritoneal dialysis days were associated with better patient survival, which has increased over time. Compared with hemodialysis days, peritoneal dialysis days were associated with a higher rate of kidney transplant, which has increased over time.

Background: Peritoneal dialysis (PD) is a form of home dialysis that is underutilized in the United States. Patients with autosomal dominant polycystic kidney disease (ADPKD) are frequently good PD candidates who are often young and have few comorbid conditions. However, clinicians may be hesitant to recommend PD to patients with ADPKD because of perceived concerns for mechanical complications and technique failure. Little is known about outcomes of patients with ADPKD undergoing PD in the United States.

Methods: A retrospective cohort of patients with ESKD 30 years and older registered in the United States Renal Data System with a diagnosis of cystic kidney disease from January 1, 2000, to December 31, 2021, was followed until death or January 1, 2023, whichever occurred first. A time-dependent variable for kidney treatment modality was created, allowing calculation of hazard ratios (HRs) and confidence intervals (CIs) on the basis of time proximity of PD exposure to death and kidney transplantation, compared with hemodialysis. Cox models were adjusted for age, sex, race, body mass index, serum albumin, hemoglobin, year of incident ESKD, insurance status, and comorbid conditions at the time of inclusion.

Results: Among 53,651 incident ADPKD patients with ESKD, 26% received some PD. Over a median follow-up of 75 months, 26,375 (49%) of the patients received kidney transplants and 23,427 (44%) died. PD exposure was more likely among patients with ADPKD who were younger, were female, and had lower burden of comorbid diseases. In the adjusted models, PD was associated with lower mortality (HR, 0.84; 95% CI, 0.80 to 0.88, P < 0.001) and higher likelihood of transplant (HR, 1.12; 95% CI, 1.08 to 1.16; P < 0.001) compared with hemodialysis. The associations with lower mortality and higher transplantation became progressively more prominent with each passing year.

Conclusions: These data indicate that PD is a safe and advantageous dialysis option for patients with ADPKD that is associated with longer patient survival and opportunities for kidney transplant.

常染色体显性多囊肾病的腹膜透析结局。
背景:腹膜透析(PD)是一种在美国未充分利用的家庭透析形式。常染色体显性多囊肾病(ADPKD)患者通常是很好的PD候选者,他们通常年轻且很少有合并症。然而,由于对机械并发症和技术失败的担忧,临床医生可能会犹豫是否向ADPKD患者推荐PD。在美国,人们对ADPKD患者接受PD治疗的结果知之甚少。方法:对2000年1月1日至2021年12月31日期间在美国肾脏数据系统登记并诊断为囊性肾病的≥30岁终末期肾病(ESKD)患者进行回顾性队列随访,直至死亡或2023年1月1日。创建了肾脏治疗方式的时间相关变量,允许基于PD暴露与死亡和肾移植的时间接近度计算风险比(HR)和置信区间(CI),与血液透析(HD)相比。Cox模型根据年龄、性别、种族、体重指数、血清白蛋白、血红蛋白、ESKD发生年份、保险状况和纳入时的合并症进行调整。结果:在53,651例合并ESKD的ADPKD患者中,26%接受了部分PD治疗。在中位随访75个月期间,26375例(49%)患者接受肾脏移植,23427例(44%)患者死亡。年轻、女性、合并症负担较低的ADPKD患者更容易出现PD暴露。在调整后的模型中,PD与较低的死亡率相关[HR: 0.84, 95% CI=0.80-0.88]。结论:这些数据表明,PD对于ADPKD患者是一种安全且有利的透析选择,与更长的患者生存期和肾移植机会相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书